

Please amend the claims as follows:

1. (Amended) A method for *in vivo* down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of

ve - at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result that immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

10. (Amended) The method according to claim 3, wherein the foreign T-cell epitope is promiscuous.

11. (Amended) The method according to claim 10, wherein the natural T-cell epitope is selected from a Tetanus toxoid epitope, a diphtheria toxoid epitope, an influenza virus hemagglutinin epitope, and a *P. falciparum* CS epitope.

12. (Twice Amended) The method according to claim 3, wherein the first moiety is selected from a

substantially specific binding partner for a B-lymphocyte specific surface antigen and a substantially specific binding partner for an APC specific surface antigen.

13. (Twice Amended) The method according to claim 3, wherein the second moiety is selected from a cytokine; a hormone; and a heat-shock protein.

14. (Twice Amended) The method according to claim 3, wherein the third moiety is of lipid nature or wherein the third moiety is a polyhydroxypolymer.

15. (Amended) The method according to claim 65, wherein the polysaccharide serves as a carrier backbone to which the amyloidogenic polypeptide and the foreign T cell epitope are separately bound.

33. (Twice Amended) The method according to claim 22, which includes at least one administration per year

Please add the following new claims:

59. (New) The method according to claim 10, wherein the foreign T-cell epitope is selected from a natural

promiscuous T-cell epitope and an artificial MHC-II binding peptide sequence.

60. (New) The method according to claim 11, wherein the tetanus toxoid epitope is selected from P2 (SEQ ID NO: 4) and P30 (SEQ ID NO: 6).

61. (New) The method according to claim 12 wherein the specific binding partner is selected from a hapten and a carbohydrate for which there is a receptor on the B-lymphocyte or the APC.

62. (New) The method according to claim 13, wherein the cytokine is selected from the group consisting of interferon γ (IFN- γ), an effective part of INF- γ , Flt3L, an effective part of Flt3L, interleukin 1 (IL-1), an effective part of IL-1, interleukin 2 (IL-2), an effective part of IL-2, interleukin 4 (IL-4), an effective part of IL-4, interleukin 6 (IL-6), an effective part of IL-6, interleukin 12 (IL-12), an effective part of IL-12, interleukin 13 (IL-13), an effective part of IL-13, interleukin 15 (IL-15), an effective part of IL-15, granulocyte-

macrophage colony stimulating factor (GM-CSF), an effective part of GM-CSF.

63. (New) The method according to claim 13, wherein the heat shock protein is selected from the group consisting of HSP70, an effective part of HSP70, HSP90, an effective part of HSP90, HSC70, an effective part of HSC70, GRP94, an effective part of GRP94, calreticulin (CRT), and an effective part of CRT.

64. (New) The method according to claim 14, wherein the third moiety is of lipid nature and is selected from the group consisting of a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group.

65. (New) The method according to claim 14, wherein the polyhydroxypolymer is a polysaccharide.

66. (New) The method according to claim 33 comprising at least 2 administrations per year.